HIGHLIGHTS
- who: HA peptide et al. from the University, Taiwan have published the article: Tumor treatment by pHLIP-targeted antigen delivery, in the Journal: (JOURNAL)
- how: The following strains were used in the study C57B1 and Balb/c female mice ranging in age from 7 to 9 weeks (both from Envigo RMS Inc.) and A3galt2 knockout female and male mice. When the progeny mice reached the age of 5-8 weeks they were used in the experiments. The Gal-pHLIP therapeutic efficacy was tested in immunized A3galt2 knockout mice using a B16F10 melanoma tumor model. HA . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.